SynthesisBMC urology2026
The effect of tranexamic acid in perioperative bleeding transfusion in radical cystectomy: a systematic review and meta-analysis.
Synthesis in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tranexamic acid in radical cystectomy: a systematic review and meta-analysis.Surgery in practice and science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTranexamic acid (TXA) is an antifibrinolytic agent with demonstrated benefits in various surgical procedures, including urological surgeries. However, its effect on radical cystectomy (RC) remains uncertain, largely due to limited data from an earlier meta-analysis that combined RC with substantially different urological procedures, as well as conflicting results from two recently published meta-analyses specifically evaluating the impact of TXA on RC.
methodsThis systematic review and meta-analysis was registered in PROSPERO (CRD42024628394) and conducted following PRISMA and Cochrane guidelines. Randomized controlled trials (RCTs) and observational studies comparing TXA versus no TXA in patients undergoing RC. Primary endpoints included perioperative blood transfusion (PBT) and venous thromboembolism (VTE). Random-effects models with Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment were used to calculate pooled risk ratios (RR) and 95% confidence intervals (CI).
resultsThree studies (one RCT and two propensity-score matched observational studies) involving 1,344 patients (673 TXA; 671 control) were included. The pooled analysis for PBT showed a non-significant reduction in risk (RR 0.69; 95% CI 0.25-1.86; p = 0.25; I2 = 81%). Similarly, the risk of VTE was not significantly different between groups, although a potential trend toward increased risk was noted (RR 1.60; 95% CI 0.80-3.17; p = 0.10; I2 = 0%).
conclusionsCurrent evidence is underpowered to confirm the efficacy or safety of TXA during radical cystectomy. While no significant benefit or harm was identified, the wide confidence intervals necessitate further large-scale randomized trials to provide definitive clinical guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.